Скачать или смотреть IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

Prof Aristotelis Bamias speaks to ecancer about the final overall survival analysis of the IMvigor130 study which atezolizumab monotherapy vs chemotherapy was used to treat untreated locally advanced or metastatic urothelial carcinoma (mUC).

The IMvigor130 primary analysis demonstrated statistically significant PFS benefit with firstline atezolizumab plus platinum/gemcitabine (Arm A) vs placebo plus platinum/gemcitabine (Arm C) in patients with metastatic urothelial carcinoma.

In the final analysis, the results demonstrated an improved OS with atezolizumab plus platinum/gemcitabine, however this did not reach statistical significance in intent-to-treat patients with mUC.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php